Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism…

January 18, 2021 08:51 ET | Source: Reports and Data

New York, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Increased investment in advanced technologies for treatment of genetic and chronic diseases is driving growth of the regenerative medicine market.Market Size USD 7.34 Billion in 2019, Market Growth - CAGR of 15.6%, Market TrendsApplications in COVID-19 vaccine.

The global regenerative medicine market is forecast to reach a market size of USD 23.57 Billion by 2027, and register a robustly incline revenue growth, according to a new report by Reports and Data. Primary factors driving demand for regenerative medicines are advancements in surgical technology and monitoring devices, and major increase in prevalence of complex and degenerative diseases. Upsurge in incidence of cancers has been resulting in increasing research into stem cell therapy. Growth in research and development activities in emerging countries and rising focus on stem cell research is resulting in significant growth in the global revenue of regenerative medicine market.

Stem cell technology is growing rapidly and continues to play a crucial role in regenerative medicine and the related field. This technology opens up the possibility of treating Parkinsons Disease, arthritis, and spinal cord injury. Increase in demand for stem cell technology is a major factor driving growth of the regenerative medicine market.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3735

Recent developments in regenerative medicine for 3D bioprinting, stem cell treatment for heart repair, and vision loss has created demand for additional investments in the R&D of the technology to help with other diseases.

The COVID-19 impact:

Demand for regenerative medicine has witnessed increased demand during the COVID-19 pandemic. Regenerative medicine helps in understanding a mechanism of infection and to develop ways to prevent the spread of the virus. It is also being used to create advanced treatments to treat persons infected by the COVID-19 virus. Private companies are also using it to develop an effective vaccine for COVID-19.

Regenerative Medicine Market Size, Share & Industry Demand By Product (Tissue-Engineered Products, Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies), By Application (Musculoskeletal Disorders, Oncology, Wound Care, By Material), and Region, Segment Forecast to 2027, To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/regenerative-medicine-market

Further key findings from the report suggest

List of Key Companies Identified in the Regenerative Medicine Market Report:

Order Now: https://www.reportsanddata.com/checkout-form/3735

For the purpose of this report, Reports and Data has segmented into the global regenerative medicine market on the basis of product, application, material, and region:

Browse similar research reports: Cell Therapy Market By Therapy Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Malignancies, Autoimmune Disorders, Musculoskeletal Disorders), By Cell Type, And By End User, Forecasts To 2027

Tissue Engineering Market Size, Growth & Analysis, By Material, By Application (Cancer, Urology, Neurology, Dental, Cell Banking & Cord Blood, Gynecology, Integumentary/Skin, Spine, Musculoskeletal, & Orthopedics, Vascular & Cardiology), And Region, Segment Forecasts To 2027

Gene Expression Market By Product And Services (Equipment, Consumables, And Services), By Capacity (Low- To Mid- Plex Gene Expression Analysis And High-Plex Gene Expression Analysis), By Application (Diagnostic, Drug Discovery, Research), And Segment Forecasts To 2027

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports And Data | Web: http://www.reportsanddata.com

Direct Line: +1-800-819-3052

E-mail: sales@reportsanddata.com

Read full Press Release at:https://www.reportsanddata.com/press-release/global-regenerative-medicine-market

Here is the original post:
Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism...

BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn Derived Exosome-Based Treatment for COVID-19 ARDS -…

NEW YORK, Jan. 20, 2021 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy. The study, entitled "MSC-NTF (NurOwn) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model," evaluated the use of NurOwn (MSC-NTF cell) derived exosomes in a mouse model of acute respiratory distress syndrome (ARDS).

ARDS is a type of respiratory failure that is frequently associated with COVID-19 and mediated by dysregulated cytokine production. While there are currently no effective therapies to prevent or reverse ARDS, mesenchymal stem cell (MSC)-derived exosomes have been suggested as a potential novel treatment option due to their ability to penetrate deep into tissues and efficiently deliver immunomodulatory molecules.

Results from the recently published study showed that intratracheal administration of NurOwn derived exosomes led to a statistically significant reduction in lung disease severity score (p < 0.05; based on criteria set forth by the American Thoracic Society Documents: Matute-Bello et al., Am J Respir Cell Mol Biol 44;725-738, 2011) and improvements in several additional clinically relevant lipopolysaccharide (LPS)-induced ARDS markers such as lung function, fibrin presence, neutrophil accumulation, cytokine expression, and blood oxygenation levels. Notably, these improvements were significantly superior to those observed following administration of nave MSC-derived exosomes.

"These exciting preclinical data suggest that NurOwn derived exosomes have the potential to treat COVID-19-induced ARDS or other severe respiratory complications, and that they are more effective than exosomes isolated from nave MSCs at combatting the various symptoms of the syndrome," said Dr. Revital Aricha, Vice President of Research & Development at BrainStorm. "This publication in a highly regarded journal provides important validation for the scientific advances and significance of BrainStorm's preclinical research programs, including on our exosome-based technology platform."

Chaim Lebovits, Brainstorm's Chief Executive Officer added, "While our primary focus is on advancing NurOwn towards regulatory approval in ALS, we continue to evaluate the potential of our exosome-based platform to address unmet medical needs. The publication of these proof-of-concept data highlights this potential, and we are now actively assessing next steps to determine how to best generate value. We are also actively discussing with possible partners several development opportunities for the exosome technology."

About NurOwn

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm is in active discussions with the FDA to identify regulatory pathways that may support NurOwn's approval in ALS. BrainStorm is also conducting an FDA-approved phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed dosing inDecember 2020, and topline results are expected by the end of the first quarter 2021.

For more information, visit the company's website atwww.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect,""likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Logo - https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

CONTACTS

Investor Relations: Corey Davis, Ph.D. LifeSci Advisors, LLC Phone: +1-646-465-1138 [emailprotected]

Media:Paul Tyahla SmithSolve Phone: +1-973-713-3768 [emailprotected]

SOURCE Brainstorm Cell Therapeutics Inc

Home

Go here to see the original:
BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn Derived Exosome-Based Treatment for COVID-19 ARDS -...

Regenerative medicine is advancing health care in diverse ways – Hometown Focus

Regenerative medicine contributed to patient care in 2020 more than ever before, bolstered by synergies in research, practice and education. Mayo Clinics Center for Regenerative Medicine is at the forefront of a biotherapy revolution in which health care advances from treating disease to restoring health.

The centrality of the body to regenerate itself is paving the way for new horizons in regenerative care. The triad of protecting against disease, preventing disease progression and promoting healing is at the core of the regenerative vision, says Andre Terzic, M.D., Ph.D., director of Mayo Clinics Center for Regenerative Medicine. To this end, the regenerative toolkit has grown more robust over the past year with new technologies now available to boost the bodys ability to repair and restore health of an organ and importantly of the patient as a whole.

The convergence of research, practice and education, empowered by strong innovation and advanced biomanufacturing, is creating an increased level of readiness for applying validated regenerative science to new areas of health care, Dr. Terzic says.

Practice advancement

A deeper understanding of the biology of health and disease is driving the ongoing regenerative medicine evolution.

The remarkable progress in science that is advancing our fundamental comprehension of both health and disease has guided the informed and responsible development of patient-ready curative strategies, says Dr. Terzic.

New discoveries at Mayo Clinic that may shape future practice include:

Validating safety and efficacy of

stem cell therapy for heart failure. The largest regenerative medicine clinical trial to date for heart failure, spanning 39 medical centers and 315 patients from 10 countries, validated the long-term safety of stem cell therapy. The late-stage research found stem cell therapy shows particular benefit for patients with advanced left ventricular enlargement. This Mayo Clinic-led study offers guidance on which patients are most likely

to respond to stem cell therapy for heart failure.

Uncovering stem cell activation of healing. Mayo Clinic researchers uncovered stem cell-activated molecular mechanisms of healing after a heart attack. Stem cells restored the makeup of failing cardiac muscle back to its condition before the heart attack, providing an intimate blueprint of how they may work to heal diseased tissue. This research offers utility to delineate and interpret complex regenerative outcomes.

Discovering a molecular light switch. Mayo Clinic research discovered a molecular switch that turns on a substance that repairs neurological damage. This early research could bolster a therapy approved by the Food and Drug Administration, and that could lead to new strategies for treating diseases of the central nervous system such as multiple sclerosis.

The federal regulatory environment is making it possible to more seamlessly integrate new discoveries into the practice. The 21st Century Cures Act, for example, seeks to create an accelerated path to market for safe, validated procedures that could provide new therapies for patients with serious conditions.

To read the rest of this article on the Center for Regenerative Medicine blog, visit http://www.regenerativemedicineblog.mayoclinic.org.

Read the original post:
Regenerative medicine is advancing health care in diverse ways - Hometown Focus

Gene Pathway Linked to Development of Schizophrenia – Psychiatric Times

In an award-winning study, researchers from The University of Texas Health Science Center at Houston (UTHealth) discovered a gene signaling pathway linked to a higher risk for developing schizophrenia by observing human-induced pluripotent stem cells created from blood samples of a single family. The pathway, phosphoinositide 3-kinase/glycogen synthase kinase 3 (PI3K/GSK3), contains differentially expressed genes, including serum-glucocorticoid kinase 1 (SGK1). This is an inhibitor of GSK3 beta and has been associated with schizophrenia.1

We believe this has direct implications for the treatment of patients, senior author Consuelo Walss-Bass, PhD, MD, said to the press. There is a new antipsychotic that just received approval from the Food and Drug Administration that directly targets the pathway we identified as dysregulated in neurons from the patients, and several other antipsychotics also target this pathway. This could help pinpoint who may respond better to treatments.2

Walss-Bass, the first author, and postdoctoral research fellow Laura Stertz, PhD, took blood samples from members of a large Costa Rican family with multiple individuals with schizophrenia. The blood cells were changed into stem cells using human-induced pluripotent stem cell (hiPSC) technology. These cells were then redirected to become brain neurons. This allowed them to be studied in a virtual biopsy and compared to neurons from family members who did not have schizophrenia.

In the biopsies, researchers saw 5 schizophrenia candidate genes previously identified by genome association studies. Alterations caused by gene SGK1, which inhibits GSK3 activity, are linked to whether a person has a higher risk of schizophrenia.

Walss-Bass had this to say on the discovery: Mental health research has lagged behind because we don't know what is happening biologically. We are diagnosing people based on what they are telling us. Even postmortem, the brain tissue in mental health disorders looks perfectly fine. In Alzheimer disease, you can see a difference compared to controls. But not in psychiatric disorders. Now by studying virtual brain biopsies, we can tell what is happening biologically.2

Walss-Bass also said that identifying patients with specific biological pathway markers could identify them as the best candidates for medications. This pre-emptive, personal pharmacology may be what is needed to best treat psychiatric disorders.

We were able to find significant, meaningful differences with a small control group, Walss-Bass said. Neurons of patients with schizophrenia had alterations in the signaling pathway. This research may help to understand how or why some antipsychotics targeting GSK3 work and also to develop other target-specific medications.2

References

1. Stertz L, Di Re J, Pei G, Fries G, et al. Convergent genomic and pharmacological evidence of PI3K/GSK3 signaling alterations in neurons from schizophrenia patients. Neuropsychopharmacol. 2020;46:673682.

2. University of Texas Health Science Center at Houston. Gene pathway linked to schizophrenia identified through stem cell engineering. News release. Science Daily. December 21, 2020. https://www.sciencedaily.com/releases/2020/12/201221134136.htm

See the article here:
Gene Pathway Linked to Development of Schizophrenia - Psychiatric Times

Humanigen Announces the Addition of BARDA and Expansion of CRADA with the US Government to Develop Lenzilumab for COVID-19 – BioSpace

Jan. 22, 2021 12:00 UTC

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc.(NASDAQ:HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab, today announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the company had previously entered into with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), to gain access to manufacturing capacity reserved by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services. The agreement supports development of lenzilumab in advance of a potential Emergency Use Authorization (EUA) for COVID-19.

The amended CRADA, now co-signed by BARDA, provides Humanigen with access to manufacturing capacity reserved by BARDA for fill-finish product to accelerate the drug product manufacturing of lenzilumab. The initial agreement, originally signed in November 2020, complements Humanigens development efforts for lenzilumab by providing access to a full-scale, integrated team of manufacturing and regulatory subject matter experts and statistical support in anticipation of applying for EUA and subsequently a Biologics License Application (BLA) for lenzilumab as a potential treatment for COVID-19. Lenzilumab is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19.

It has been an honor to have the integrated expert team at BARDA prioritize lenzilumab research and development during this critical time, said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. As we move closer to filing a potential EUA, the integrated support of BARDA and JPEO helps us with manufacturing capabilities as we ready operations to support access to lenzilumab.

Humanigen's investigational treatment lenzilumab, a proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, is designed to prevent and treat an immune hyper-response called cytokine storm, a complication considered to be a leading cause of COVID-19 death. Data showed that up to 89 percent of hospitalized patients with COVID-19 are at risk of this immune hyper-response, which is believed to trigger the acute respiratory distress syndrome in severe cases of COVID-19.

More details on Humanigens programs in COVID-19 can be found on the companys website under the COVID-19 tab. Details on the U.S. Phase 3 lenzilumab clinical trial can be found at clinicaltrials.gov using Identifier NCT04351152. Details on ACTIV-5/BET can be found at clinicaltrials.gov using Identifier NCT04583969.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. Humanigens immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. Humanigen is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com and follow Humanigen on LinkedIn, Twitter and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although Humanigen management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding the use of lenzilumab to treat patients hospitalized with COVID-19, Humanigens expectations regarding the timeline to file for and obtain EUA, as well as a potential BLA filing, statements regarding Humanigens ability to attain necessary manufacturing support, and statements regarding Humanigens beliefs relating to any of the other technologies in Humanigens current pipeline. These forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in Humanigens lack of profitability and need for additional capital to grow Humanigens business; Humanigens dependence on partners to further the development of Humanigens product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory approvals or authorization for emergency or broader patient use for the product candidate and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Humanigen's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. Humanigen undertakes no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005079/en/

Link:
Humanigen Announces the Addition of BARDA and Expansion of CRADA with the US Government to Develop Lenzilumab for COVID-19 - BioSpace

Cell Sorting Market Size to Reach USD 805.1 Million By 2027 | Expanding Biotechnology And Pharmaceutical Industries will be the Major Factor Driving…

Advancements in technology and increased funding for research and development of cell sorting are key factors driving growth of the cell sorting market.

New York, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The global cell sorting market is projected to reach a market size of USD 805.1 Million by 2027 and register a high revenue CAGR during the forecast period, according to a latest report by Reports and Data. Global cell sorting market revenue growth is expected to be driven by expansions and developments in biotechnology and pharmaceutical industries, and rising investment in research & development initiatives and projects.

Increase in healthcare budgets in developing economies and rise in need for development of targeted therapies are other key factors driving growth of the cell sorting market. Advancements in biotechnology and increase in adoption of cell sorters for research and development activities are also expected to fuel growth of the market over the forecast period. The global cell sorting market is consolidated and complex in nature, with major international players accounting for a significant market revenue share. This also limits entry of new players into the market. In addition, emergence of microfluidics technology for cell sorting is expected to open up new and more lucrative opportunities for companies operating in this market.

However, lack of awareness regarding cell sorting is expected to limit adoption in developing economies to a certain extent in the near future.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3748

The COVID-19 Impact:

During the COVID-19 pandemic, demand for cell sorting surged at a rapid rate. The need to develop an efficient and cost-effective vaccine and therapy for COVID-19 has driven demand for cell sorting in clinical research to a new high. Investments in research to develop an effective vaccine for COVID-19 continue to rise, which is expected to support market growth going ahead.

Story continues

Further Key Findings from the Report Suggest

The cell sorters segment accounted for the largest revenue share in the global cell sorting market in 2019. Emergence of advanced cell sorters has enabled resolving several issues related to cell sorting procedures, resulting in quicker decisions. .

The micro-electro mechanical system (MEMS) technology, which comprises nano-imprint, lithography, and dry and wet etching, is employed to manufacture microfluidic devices with a wide range of substrate materials such as glass, silicon, metals, and polymers. Growing application of the technology in wells, nozzles, channels, and jets, is expected to drive growth of the MEMS segment over the forecast period.

Increase in cellular analysis activities in the fields of stem cells research, cancer research, cell engineering, drug discovery, and protein engineering boosted revenue growth of the research application segment in 2019.

Revenue from the Asia Pacific cell sorting market is growing at the highest rate currently, and can be attributed to rising prevalence of cancer among individuals in countries in the region. Additionally, growth of pharmaceutical and biotechnology industries in the region is also propelling growth of the cell sorting market.

Key participants include Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Miltenyi Biotec GmbH, Sysmex Partec GmbH, Beckman Coulter, Inc., On-Chip Biotechnologies Co., Ltd., Sony Biotechnology Inc., Affymetrix, Inc., Thermo Fisher Scientific, Inc., and Union Biometrica, Inc.

Buy Your Copy Now (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3748

For the purpose of this report, Reports and Data has segmented the global cell sorting market on the basis of product and services, technology, application, end-use, and region:

Product and Services Outlook (Revenue, USD Million; 2017-2027)

Cell Sorters

Reagents & Consumables

Services

Technology Outlook (Revenue, USD Million; 2017-2027)

Application Outlook (Revenue, USD Million; 2017-2027)

Clinical

Research

Stem Cell Research

Immunology & Cancer Research

Drug Discovery

Others

End-use Outlook (Revenue, USD Million; 2017-2027)

Medical Schools & Academic Institutions

Research Institutions

Hospitals & Clinical Testing Laboratories

Pharmaceutical and Biotechnology Companies

Click on the link to read key highlights of the report and look at projected trends for years to come: https://www.reportsanddata.com/report-detail/cell-sorting-market

Take a Look at our Related Reports:

Bioprosthetics Market: The increasing prevalence of rheumatoid heart disease, coronary and peripheral artery diseases, and other cardiovascular diseases have led to the increasing demand for long-term treatment and relief, factors that are anticipated to drive bioprosthetics market growth.

Stone Treatment Devices Market: Factors such as mounting geriatric populace, an expansion in the frequencies of stone formation, upsurge in the recurrence of the stone after a medical procedure, a tendency towards minimally invasive procedures are expected to propel the industry in the coming years.

Automated Insulin Delivery Systems Market: Automated Insulin Delivery Systems is an user friendly technology that regulate blood glucose level with the help of continuous glucose monitoring.

Cerebrospinal Fluid (CSF) Management Market: The unique nature of cerebrospinal fluid dynamics in each patient has challenged neurologists, neurosurgeons, and medical device developers. This has led to cumulative demand for advanced cerebral spinal fluid (CSF) management devices.

Sacral Neuromodulation Market: A rise in the prevalence of overactive bladder & urge continence among masses along with the expansion of the geriatric population base across the globe is the key factor driving the market growth.

Central Venous Catheters Market: Catheters are an efficient delivery mechanism for surgical procedures. These are medical devices, which are used for the treatment of a large number of cardiovascular diseases and other chronic disorders.

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports And Data | Web: http://www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

LinkedIn | Twitter | Blogs

Read Full Press Release@ https://www.reportsanddata.com/press-release/global-cell-sorting-market

Original post:
Cell Sorting Market Size to Reach USD 805.1 Million By 2027 | Expanding Biotechnology And Pharmaceutical Industries will be the Major Factor Driving...

BrainStorm’s Covid-19 ARDS treatment improves lung function in study – Clinical Trials Arena

BrainStorm Cell Therapeutics has announced that its NurOwn (MSC-NTF cell) derived exosomes provided significant improvement in lung function and histology in an acute respiratory distress syndrome (ARDS) mouse model, in a preclinical study.

Mesenchymal stem cell (MSC)-derived exosomes can penetrate deep into tissues and deliver immunomodulatory molecules effectively.

A type of respiratory failure, ARDS is linked to Covid-19 and is mediated by dysregulated cytokine production.

Intratracheal administration of NurOwn derived exosomes provided a statistically significant reduction in lung disease severity score, the study data showed.

Furthermore, improvements in lipopolysaccharide (LPS)-induced ARDS markers like lung function, fibrin presence, neutrophil accumulation, cytokine expression and oxygenation levels in the blood, were observed.

These improvements were significantly superior to those noticed following nave MSC-derived exosome administration.

BrainStorm Research and Development vice-president Dr Revital Aricha said: These exciting preclinical data suggest that NurOwn derived exosomes have the potential to treat Covid-19-induced ARDS or other severe respiratory complications and that they are more effective than exosomes isolated from nave MSCs at combatting the various symptoms of the syndrome.

This publication in a highly regarded journal provides important validation for the scientific advances and significance of BrainStorms preclinical research programs, including on our exosome-based technology platform.

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business.

MSC-NTF cells are made from autologous, bone marrow-derived MSCs expanded and separated ex vivo.

Brainstorm CEO Chaim Lebovits said: While our primary focus is on advancing NurOwn towards regulatory approval in ALS, we continue to evaluate the potential of our exosome-based platform to address unmet medical needs.

In December 2019, the company received a recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the Phase II clinical trial of NurOwn in progressive multiple sclerosis patients.

Electronic Data Capture Solutions for Clinical Trials

28 Aug 2020

Contract Manufacturing Organisation and Pharmaceutical Supply Services

28 Aug 2020

Visit link:
BrainStorm's Covid-19 ARDS treatment improves lung function in study - Clinical Trials Arena

Impact of Covid-19 on Automated Cell Culture Market Influencing the Industry Development and Forecast | BD, Tecan Trading, Sartorius, TAP Biosystems,…

Reports Monitor has recently added a new report to its vast depository titledGlobal Automated Cell Culture Market. The report studies vital factors about theGlobal Automated Cell Culture Marketthat are essential to be understood by existing as well as new market players. The report highlights the essential elements such as market share, profitability, production, sales, manufacturing, advertising, technological advancements, key market players, regional segmentation, and many more crucial aspects related to theGlobal Automated Cell Culture Market.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

The following Top manufacturers are evaluated in this report: BD, Tecan Trading, Sartorius, TAP Biosystems, Cell Culture Company, Eppendorf, Merck KGaA, Hamilton Company, Thermo Fisher Scientific, OCTANE BIOTECH & amp; More.

More Insightful information | Request a sample copy @ https://www.reportsmonitor.com/request_sample/1005622

Product Type Segmentation Automated Cell Culture Storage Equipment Automated Cell Culture Vessels Automated Cell Culture Supporting Instruments Bioreactors

Industry Segmentation Drug Development Stem Cell Research Cancer Research

Some of the main geographic regions included in this report are: 1. North America (United States and Canada and rest of North America) 2. Europe (Germany, France, Italy and the rest of Europe) 3. Asia-Pacific (China, Japan, India, South Korea and the rest of Asia-Pacific) 4. LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and the rest of LAMEA)

Grab Your Report at an Impressive Discount ! Please click Here @https://www.reportsmonitor.com/check_discount/1005622

What does the report offer?

The Global Automated Cell Culture Market report analyzes the production of goods, supply, sales and the current state of the market in detail. In addition, the report examines the market share of production and sales of products, as well as capacity, production capacity, sales trends, cost analysis and revenue generation. Several other factors such as import / export status, industrial statistics, supply and demand ratio, gross margin and the structure of the industrial chain were also studied in the Global Automated Cell Culture Reports.

Get the full report with TOC Please click here @ https://www.reportsmonitor.com/report/1005622/Automated-Cell-Culture-Market

To conclude, the Automated Cell Culture report mentions the key geographies, the market landscapes as well as the product price, revenues, volume, production, supply, demand, rate of market growth and forecasts etc. This report also provides a SWOT analysis, an investment feasibility analysis and a return on investment. analysis.

Contact us Jay Matthews Direct: +1 513 549 5911 (U.S.) +44 203 318 2846 (U.K.) Email: sales@reportsmonitor.com

The rest is here:
Impact of Covid-19 on Automated Cell Culture Market Influencing the Industry Development and Forecast | BD, Tecan Trading, Sartorius, TAP Biosystems,...